
Jacek Jerzy JÃ³Å^owiak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3662471/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
2	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet, The, 2017, 390, 2627-2642.	13.7	5,010
3	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989
4	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	13.7	3,269
5	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	13.7	2,858
6	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
7	Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Clobal Burden of Disease Study 2019. Lancet Neurology, The, 2021, 20, 795-820.	10.2	2,308
8	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
9	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
10	Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	10.2	2,005
11	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
12	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 2018, 379, 2429-2437.	27.0	959
13	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 245-266.	8.1	823
14	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
15	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
16	Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature, 2019, 569, 260-264.	27.8	469
17	EU-Wi <i>d</i> e Cross-Section <i>a</i> l Obser <i>v</i> at <i>i</i> o <i>n</i> al Study of Lipid-Modifying Therapy Use in Se <i>c</i> ondary and Pr <i>i</i> mary Care: the DA VINCI study. European Journal of Preventive Cardiology, 2021, 28, 1279-1289.	1.8	369
18	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	13.7	335

Jacek Jerzy JóÅ⁰wiak

#	Article	IF	CITATIONS
19	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
20	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
21	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	27.8	161
22	Mapping child growth failure across low- and middle-income countries. Nature, 2020, 577, 231-234.	27.8	128
23	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i96-i114.	2.4	103
24	The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis. The Lancet Global Health, 2020, 8, e1186-e1194.	6.3	98
25	PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Archives of Medical Science, 2021, 17, 1447-1547.	0.9	78
26	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.9	70
27	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019. Lancet Regional Health - Europe, The, 2022, 16, 100341.	5.6	70
28	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. International Journal of Epidemiology, 2018, 47, 872-883i.	1.9	65
29	Mapping disparities in education across low- and middle-income countries. Nature, 2020, 577, 235-238.	27.8	58
30	Global trends of hand and wrist trauma: a systematic analysis of fracture and digit amputation using the Global Burden of Disease 2017 Study. Injury Prevention, 2020, 26, i115-i124.	2.4	51
31	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. International Journal of Epidemiology, 2020, 49, 173-192.	1.9	44
32	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i125-i153.	2.4	44
33	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Clobal Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
34	2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Archives of Medical Science, 2020, 16, 237-252.	0.9	37
35	Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. BMC Cardiovascular Disorders, 2019, 19, 11.	1.7	36
36	Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. PLoS ONE, 2020, 15, e0226766.	2.5	33

JACEK JERZY JÃ³źWIAK

#	Article	IF	CITATIONS
37	Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids in Health and Disease, 2019, 18, 188.	3.0	31
38	Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis, 2021, 334, 66-75.	0.8	29
39	Association between anthropometric obesity measures and coronary artery disease: a cross-sectional survey of 16 657 subjects from 444 Polish cities. Heart, 2010, 96, 131-135.	2.9	28
40	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. European Heart Journal, 2018, 39, 3635-3640.	2.2	25
41	Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study. Atherosclerosis, 2020, 312, 16-22.	0.8	25
42	Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018. Nature Human Behaviour, 2021, 5, 1027-1045.	12.0	24
43	Renal Mechanisms of Association between Fibroblast Growth Factor 1 and Blood Pressure. Journal of the American Society of Nephrology: JASN, 2015, 26, 3151-3160.	6.1	20
44	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atherosclerosis Supplements, 2020, 42, e15-e24.	1.2	18
45	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
46	The Relation of Rapid Changes in Obesity Measures to Lipid Profile - Insights from a Nationwide Metabolic Health Survey in 444 Polish Cities. PLoS ONE, 2014, 9, e86837.	2.5	15
47	Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 287-296.	2.8	14
48	Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. PLoS Neglected Tropical Diseases, 2021, 15, e0008824.	3.0	10
49	Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2020, 18, 604-616.	0.9	9
50	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	2.4	9
51	Oxidative Stress Markers in Hypertrophic Cardiomyopathy. Medicina (Lithuania), 2022, 58, 31.	2.0	9
52	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. Archives of Public Health, 2022, 80, 142.	2.4	9
53	Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviews. BMJ Open, 2017, 7, e014206.	1.9	8
54	Treatment of hypertension in central and eastern European countries. Journal of Hypertension, 2012, 30, 1671-1678.	0.5	7

#	Article	IF	CITATIONS
55	Do we know more about hypertension in Poland after the May Measurement Month 2017?—Europe. European Heart Journal Supplements, 2019, 21, D97-D100.	0.1	6
56	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study FromÂDA VINCI. Cardiovascular Drugs and Therapy, 2023, 37, 941-953.	2.6	6
57	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	3.0	5
58	Treatment targets in patients with type 2 diabetes set by primary care physicians from Central and Eastern Europe. European Journal of General Practice, 2014, 20, 253-259.	2.0	4
59	PROGENS-HbA 1c study: safety and effectiveness of premixed recombinant human insulin (Gensulin) Tj ETQq1 1 (0.784314	rg&T /Over
60	May Measurement Month 2018: an analysis of blood pressure screening campaign results from Poland. European Heart Journal Supplements, 2020, 22, H108-H111.	0.1	4
61	Diagnostic Accuracy of Clycated Haemoglobin and Average Clucose Values in Type 2 Diabetes Mellitus Treated with Premixed Insulin. Diabetes Therapy, 2019, 10, 587-596.	2.5	2
62	May Measurement Month 2019: an analysis of blood pressure screening results from Poland. European Heart Journal Supplements, 2021, 23, B124-B127.	0.1	2
63	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.9	2
64	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. Journal of Clinical Medicine, 2021, 10, 4472.	2.4	2
65	Lipids profile and efficacy of treatment of dyslipidemia in primary care in Poland. Results of lipidogram 5 years study (2004–2010). Atherosclerosis, 2017, 263, e187.	0.8	1
66	Wytyczne PTL/KLRwP/PTK dotyczące postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016. Kardiologia Polska, 2017, 74, 127-168.	0.6	1
67	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. Archives of Medical Science, 2021, ,	0.9	1
68	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	2.5	1
69	Usefulness of atherogenic dyslipidemia index to assess the cardiovascular risk of primary care patients – Results from lipidogram 2004 and lipidogram 2006 studies. Atherosclerosis, 2017, 263, e265.	0.8	0
70	2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna I WiadomoÅci PTDL, 2021, 57, 1-99.	0.1	0
71	The prevalence rate of overweight and obesity among adult patient population in Poland, according to the LIPIDOGRAM2004 and LIPIDOGRAM2006 studies, in context of previous Polish national screening surveys. Przeglad Lekarski, 2011, 68, 316-9.	0.1	0